Date published: 2026-7-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

Unc18-2 CRISPR Activation Plasmid (h): sc-403691-ACT

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • Unc18-2 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
  • Unc18-2 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
  • The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
  • gRNAs encoded by Unc18-2 CRISPR Activation Plasmid (h) and Unc18-2 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the STXBP2 transcriptional start site. One or both designs may be available
  • Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Unc18-2 Antibody (B-2): sc-376639
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    Unc18-2 CRISPR Activation Plasmid (h)

    sc-403691-ACT
    20 µg
    $397.00

    STXBP2 encodes syntaxin-binding protein 2 (Unc18-2), a Sec1/Munc18 family regulator of SNARE complex assembly required for vesicle docking and membrane fusion. In immune cells, Unc18-2 supports cytotoxic granule exocytosis and regulated secretion, integrating with pathways controlling degranulation, endolysosomal trafficking, and membrane remodeling. Altered STXBP2 function has been linked to immune dysregulation phenotypes, making it relevant for studying vesicle-mediated secretion defects and downstream inflammatory signaling programs. Its activity is also informative in broader contexts of secretory pathway control, including receptor recycling and cell-cell communication.

    Unc18-2 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous STXBP2 expression without altering the underlying DNA sequence.

    Unc18-2 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the STXBP2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

    Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the STXBP2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Unc18-2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native STXBP2 locus and enabling the study of Unc18-2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Unc18-2 pathway restoration in tumor cells with silenced or reduced STXBP2 expression.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.